Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.35 |
| ▸ | JAK1 | P23458 | 2/20 | 0.35 |
| ▸ | TYK2 | P29597 | 2/20 | 0.35 |
| ▸ | JAK3 | P52333 | 2/20 | 0.35 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.33 |
| ▸ | CTSS | P25774 | 6/20 | 0.33 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 2/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | CDK7 | P50613 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20550680 | 0.89 | TRPV1 (0.40) | JAK2JAK1TYK2JAK3CTSS | |
| SCHEMBL17770356 | 0.88 | LOXL2 (0.35) | JAK2JAK1TYK2JAK3SCN10A | |
| SCHEMBL17770109 | 0.88 | LOXL2 (0.35) | JAK2JAK1TYK2JAK3SCN10A | |
| SCHEMBL17769550 | 0.86 | AXL (0.34) | ACACB | |
| SCHEMBL17769549 | 0.86 | AXL (0.34) | ACACB | |
| SCHEMBL17769663 | 0.86 | OPRK1 (0.34) | CHEK1GSK3B | |
| SCHEMBL20550605 | 0.85 | GSK3B (0.43) | GSK3B | |
| SCHEMBL17769634 | 0.84 | TRPV1 (0.39) | JAK2JAK1TYK2JAK3CTSS | |
| SCHEMBL17769352 | 0.83 | OPRK1 (0.42) | — | |
| SCHEMBL17769757 | 0.83 | OPRK1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180319810-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2018-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180319810-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | JAK2 1856/4885JAK1 2463/4885TYK2 2258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.